Histone deacetylase inhibitor

Muscular Dystrophy Association’s Funding of Foundational Research Leads to New FDA Approved Treatment Duvyzat (givinostat) for Duchenne Muscular Dystrophy

Retrieved on: 
Thursday, March 21, 2024
HDAC, Gene expression, Cell, Disease, MDA, Associate, Patient, Research, DNA, Public policy, University, Muscular dystrophy, Doctor of Philosophy, Muscular Dystrophy Association, Duchenne muscular dystrophy, Clinical trial, Therapy, Histone deacetylase inhibitor, Stair climbing, Plasma protein binding, FDA, Steroid, DMD, Parent, Lancet, Pediatrics, Human, Food, Pharmaceutical industry

"The approval of Duvyzat (givinostat) provides another significant treatment option for people living with Duchenne muscular dystrophy,” said Sharon Hesterlee, PhD, Chief Research Officer, MDA.

Key Points: 
  • "The approval of Duvyzat (givinostat) provides another significant treatment option for people living with Duchenne muscular dystrophy,” said Sharon Hesterlee, PhD, Chief Research Officer, MDA.
  • “Muscular Dystrophy Association’s funding was fundamental for the discovery of HDACi in the treatment of Duchenne muscular dystrophy.
  • “We’re excited to celebrate this additional treatment option for people living with Duchenne muscular dystrophy.
  • My son is an example,” said Jessica Curran, MDA family member and mother of Conner who lives with Duchenne muscular dystrophy.

Three Articles in the Journal of Pharmaceutical Analysis Uncover Previously Unknown Drug and Disease Mechanisms

Retrieved on: 
Friday, December 15, 2023
Kidney, OAT, Chronic pain, Live Phish Volume 13, Hope, Colorectal cancer, Acute kidney injury, Recycling, CRC, Cytoplasm, Mouse, Analgesic, MRP4, MOR, Dicarboxylic acid, Endocytosis, Cancer, Kynurenic acid, Morphine, Biomarker, Rat, CDK5, JPA, Histone deacetylase inhibitor, Pharmaceutical industry

XI'AN, China, Dec. 15, 2023 /PRNewswire/ -- Long-term use of analgesics such as morphine leads to "tolerance" that reduces drug efficacy. In such cases, dose escalation may be required to achieve the same analgesic effects. The key molecular mechanism of morphine tolerance is its inefficiency in inducing mu-opioid receptor (MOR) endocytosis. None of the currently available strategies to counter morphine tolerance address this underlying molecular mechanism. Moreover, understanding how drugs work is crucial to determine their efficacy. There is also an unmet need for new diagnostic biomarkers that can help identify diseases at an early stage. The October issue of JPA features three articles that address these issues and systematically lay a foundation for future studies and treatment strategies.

Key Points: 
  • XI'AN, China, Dec. 15, 2023 /PRNewswire/ -- Long-term use of analgesics such as morphine leads to "tolerance" that reduces drug efficacy.
  • The October issue of JPA features three articles that address these issues and systematically lay a foundation for future studies and treatment strategies.
  • In the second study , researchers dug deeper into the anticancer mechanisms of the drug 'pracinostat,' which is a histone deacetylase inhibitor (HDACi).
  • Corresponding author Prof. Xinan Wu speculates by saying, "Our findings could aid in adjusting drug dosage or predicting renal injury via OAT channels."

Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphoma

Retrieved on: 
Tuesday, August 8, 2023
Lymphoma, PTCL, Peripheral T-cell lymphoma, Hematopoietic stem cell transplantation, ASH, Angioimmunoblastic T-cell lymphoma, Lymphoproliferative disorders, Creatinine, DLBCL, Thomas Jefferson University, Aes, Valganciclovir, Constipation, Oncology, Histone deacetylase inhibitor, B-cell lymphoma, Bone marrow, Patient, Division, American Society of Hematology, Data, SAN, PTLD, PTCL-NOS, Cytopenia, Nausea, Paper, CRS, Therapy, Society, ORR, Disease, Vaccine, Pharmaceutical industry, Hematology

SAN DIEGO, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced the publication of clinical data from an open-label, multicenter, Phase 1b/2 study of Nana-val in 55 patients with R/R EBV+ lymphoma in Blood Advances. Results showed complete responses (CRs) achieved and ongoing durable responses observed out to approximately 36 months across multiple EBV+ lymphoma subtypes, including some of the most aggressive cancers: peripheral T-cell lymphoma (PTCL), diffuse large B-cell lymphoma (DLBCL), and post-transplant lymphoproliferative disease (PTLD). This paper titled, “Targeted therapy with nanatinostat and valganciclovir in recurrent Epstein-Barr virus-positive lymphoid malignancies: a Phase 1b/2 study,” can be found here.

Key Points: 
  • This paper titled, “Targeted therapy with nanatinostat and valganciclovir in recurrent Epstein-Barr virus-positive lymphoid malignancies: a Phase 1b/2 study,” can be found here .
  • The published paper includes an additional 10-month follow-up period, which demonstrated durable response durations across multiple EBV+ lymphoma subtypes.
  • Overall, trial participants received a median of two prior therapies before entering the trial, with 75% (41/55) being refractory to their last therapy.
  • Initial data from the Nana-val Phase 1b/2 clinical trial were previously presented at the 2021 American Society of Hematology (ASH) Annual Meeting .

Terns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology

Retrieved on: 
Monday, March 27, 2023
TKI, Allosteric regulation, MDM2, Employment, Novartis Institute for Tropical Diseases, Obesity, Biomedical Research, Therapy, NASH, NIBR, CML, Cancer, Research, Acute leukemia, Histone deacetylase inhibitor, University of Texas Southwestern Medical Center, Novartis, Memorial Sloan Kettering Cancer Center, Fatty liver disease, Weill Cornell Medicine, Mount Athos, Pharmaceutical industry, Nursing, Neuroscience, New York University, Tern

as chief medical officer of Terns oncology, effective May 1, 2023.

Key Points: 
  • as chief medical officer of Terns oncology, effective May 1, 2023.
  • Dr. Kuriakose brings more than a decade of clinical development and medical affairs experience spanning early through late phase development in several oncology indications at Novartis and Calithera Biosciences, where he most recently was serving as chief medical officer.
  • After Dr. Kuriakose commences his employment at Terns, Kerry Russell, M.D., will assume the role of chief medical officer of Terns metabolic with responsibility for Terns’ NASH and obesity programs.
  • I look forward to leveraging my experience to advance TERN-701 for the treatment of CML and expand Terns’ oncology franchise,” commented Dr. Kuriakose.

Precision Cancer Therapeutics Markets, 2022 - Focus on Monoclonal Antibodies, Kinase Inhibitors, Angiogenesis Inhibitors, Proteasome Inhibitors, & CAR-T therapies - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 27, 2022
Health, Oncology, Cancer, Stomach, Therapy, Lung, PI3K, CDK, Breast, Histone deacetylase inhibitor, Prostate, Loss Time Life, Patient, PARP, Liver, Medical device, Pharmaceutical industry, Medical imaging

The "Precision Cancer Therapeutics, 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Precision Cancer Therapeutics, 2022" report has been added to ResearchAndMarkets.com's offering.
  • Precision Cancer Therapeutics, 2022 focuses on the expanding area of precision cancer therapies and includes current products available and discusses some of the most exciting developments in progress.
  • Today, advanced precision cancer therapies are available, and more are being developed each year.
  • This report covers precision cancer therapies that do at least one of the following:
    Carry toxins to the cancer cells to kill them, but not normal cells
    This report Precision Cancer Therapeutics, 2022 specifically focuses on five leading segments of precision therapies:

Insights on the Histone Deacetylase Inhibitors Global Market to 2027 - Rising Adoption of Advanced Technologies and Collaboration Among Manufacturers and Companies Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Monday, October 3, 2022
Health, Pharmaceutical, Technology, Value, Certification, CAGR, Market share analysis, Decision-making, R, COVID-19, Customer support, Growth, Histone deacetylase inhibitor, USD, Strategic management, Business Growth Fund, Acquisition, Use, Investment, Retail, Fine chemical, Fertilizer

What are the inhibiting factors and impact of COVID-19 shaping the Global Histone Deacetylase Inhibitors Market during the forecast period?

Key Points: 
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Histone Deacetylase Inhibitors Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Histone Deacetylase Inhibitors Market?
  • What is the market share of the leading vendors in the Global Histone Deacetylase Inhibitors Market?
  • What modes and strategic moves are considered suitable for entering the Global Histone Deacetylase Inhibitors Market?

Nitrase Therapeutics Expands Pipeline to Include Oncology Programs and Adds Seasoned Cancer Experts to Scientific Advisory Board

Retrieved on: 
Thursday, June 2, 2022
Histone deacetylase inhibitor, Yale University, The Michael J. Fox Foundation, Divisional Railway Hospital, Golden Rock, Investment, Therapy, Moses Austin, United States Air Force Scientific Advisory Board, AbbVie, Immune system, Novartis Institute for Tropical Diseases, Medicine, Cancer, MJFF, Berkeley, Pathology, University of Maryland, College Park, Cardiovascular disease, SAB, Sofinnova, CA, Biomedical Research, Biology, Cancer research, University of California, San Francisco, Bristol Myers Squibb, University, DRS, Acquisition, Vanderbilt University, Internal medicine, Enzyme, Chiron Corporation, Head, Michael J. Lenardo, Research, UCSF, FDA, GLOBE, San Francisco, Novartis, Board, Nitration, Biophysics, Protein, Pharmaceutical industry, Chemistry

We have discovered that several nitrases and their nitro-substrates play an important role in cancer, both in cancer and in immuno-oncology.

Key Points: 
  • We have discovered that several nitrases and their nitro-substrates play an important role in cancer, both in cancer and in immuno-oncology.
  • With the launch of our oncology program to discover and develop therapeutics against these identified nitrases, we are thrilled to have attracted Drs.
  • Dr. Davidsen added, I am impressed by Nitrase Therapeutics remarkable discovery of a large number of nitrases with broad and diverse biology.
  • I look forward to working with the management team at Nitrase Therapeutics to bring truly unique medicines to patients.

Kyowa Kirin International: New Real World Evidence Underlines Benefits of POTELIGEO®▼ (mogamulizumab) Treatment for Cutaneous T-cell Lymphoma (CTCL) Patients

Retrieved on: 
Thursday, October 14, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Product, Incidence, Roger Hawkins (drummer), Lymphocytopenia, Degenerative disease, Kyowa Hakko Kirin, Asia, Neurology, FDA, Disease, Itch, Sleep, Lymph, Research, MF, Weakness, Non-Hodgkin lymphoma, Blood, B-cell lymphoma, Engineering, Cutaneous T cell lymphoma, Medication package insert, T-cell lymphoma, Patient, Life, CC, Lymphocyte, Family, Saint Louis Hospital (Bangkok), ORR, Diagnosis, Dermatitis, Erythroderma, Vorinostat, Skin, SS, Histone deacetylase inhibitor, Kirin, Pain, Adult, Rash, NHL, CCR4, Malignancy, Mycosis fungoides, Nephrology, Hair loss, EORTC, Hospital, Safety, Pharmaceutical industry, Vaccine, Medical imaging, Mycosis Fungoides (MF) and Sézary syndrome (SS), POTELIGEO, Kyowa Kirin, MYCOSIS FUNGOIDES (MF) AND SéZARY SYNDROME (SS), POTELIGEO, KYOWA KIRIN

Kyowa Kirin International PLC (Kyowa Kirin), a wholly owned subsidiary of Kyowa Kirin Co., Ltd., today announced a new study of real world data showing higher response rates than previously seen in people living with cutaneous T-cell lymphoma (CTCL) treated with POTELIGEO (mogamulizumab).

Key Points: 
  • Kyowa Kirin International PLC (Kyowa Kirin), a wholly owned subsidiary of Kyowa Kirin Co., Ltd., today announced a new study of real world data showing higher response rates than previously seen in people living with cutaneous T-cell lymphoma (CTCL) treated with POTELIGEO (mogamulizumab).
  • The best overall response rate (ORR) seen in the real-life study was 47.0% in MF patients and 68.3% in SS patients.
  • In contrast, the ORRb in MAVORIC was 21% and 37%, respectively.1,2 Of the 124 patients who received POTELIGEO treatment in the study, 44% were MF patients and 56% were SS patients.
  • Its heartening to see this new real world data, which reinforces what weve seen previously in clinical trials.

Syndax to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11, 2021

Retrieved on: 
Tuesday, May 4, 2021
Life sciences, Pharmaceutical industry, Biotechnology, Health sciences, Antineoplastic drugs, Cytokines, Biopharmaceutical, Pharmacy, Medication, Histone deacetylase inhibitor, Macrophage colony-stimulating factor

b'WALTHAM, Mass., May 4, 2021 /PRNewswire/ --Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its first quarter 2021 financial results on Tuesday, May 11, after the close of the U.S. financial markets.\nIn connection with the earnings release, Syndax\'s management team will host a conference call and live audio webcast at 4:30 p.m.

Key Points: 
  • b'WALTHAM, Mass., May 4, 2021 /PRNewswire/ --Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its first quarter 2021 financial results on Tuesday, May 11, after the close of the U.S. financial markets.\nIn connection with the earnings release, Syndax\'s management team will host a conference call and live audio webcast at 4:30 p.m.
  • ET on Tuesday, May 11, to discuss the Company\'s financial results and provide a general business update.\nThe live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company\'s website at www.syndax.com .
  • The Company\'s pipeline includes SNDX-5613, a highly selective inhibitor of the MeninMLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor.
  • For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn .\n'

KYAN Therapeutics Exclusively Licenses Small Molecule HDAC Inhibitors for AI-Powered Cancer Drug Development

Retrieved on: 
Thursday, September 24, 2020
Antineoplastic drugs, Kyan, Histone deacetylase inhibitor, Histone deacetylase, Cancer

SINGAPORE, Sept. 24, 2020 /PRNewswire/ -- KYAN Therapeutics, Inc. ("KYAN"), a frontier biotech company with a novel drug-dose combination optimizing platform, Optim.AI, has entered into an exclusive license agreement with Georgetown University for novel selective Class II HDAC inhibitors.KYAN has already commenced preclinical development of the lead candidate, which has been designated as KYAN-001, with early positive results.

Key Points: 
  • SINGAPORE, Sept. 24, 2020 /PRNewswire/ -- KYAN Therapeutics, Inc. ("KYAN"), a frontier biotech company with a novel drug-dose combination optimizing platform, Optim.AI, has entered into an exclusive license agreement with Georgetown University for novel selective Class II HDAC inhibitors.KYAN has already commenced preclinical development of the lead candidate, which has been designated as KYAN-001, with early positive results.
  • In vitro and in vivo studies of KYAN-001 have shown high efficacy for Multiple Myeloma and Prostate Cancer.The low toxicity and metabolic stability of KYAN-001 indicates a better safety and tolerability profile than FDA approved pan-HDAC inhibitors which suffer from toxicity issues and side effects.KYAN-001 also uniquely inhibits HDAC4 nucleoshuttling to further drive its anti-cancer effects.
  • "We're very excited to proceed with KYAN-001 because of its promising features and we are confident that we can identify optimal combination therapies across multiple cancer indications with Optim.AI," said Lisa Chow, COO and General Counsel of KYAN.
  • KYAN plans to explore at least four cancer indications for KYAN-001 and anticipates advancing KYAN-001 through to Phase I clinical trials by 2022.